Cyclerion Therapeutics (NASDAQ:CYCN) Issues Earnings Results, Beats Estimates By $6.69 EPS

Cyclerion Therapeutics (NASDAQ:CYCN) posted its quarterly earnings results on Tuesday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.10) by $6.69, FiscalAI reports. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%.

Cyclerion Therapeutics Price Performance

Shares of CYCN opened at $3.51 on Wednesday. The firm has a 50 day simple moving average of $3.37 and a two-hundred day simple moving average of $2.62. Cyclerion Therapeutics has a one year low of $1.03 and a one year high of $8.48. The company has a market cap of $16.43 million, a P/E ratio of -2.58 and a beta of 1.76.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent filing with the SEC. Institutional investors own 75.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cyclerion Therapeutics has a consensus rating of “Sell”.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.